healthy choice glp-1 meals Frozen & Treats Thats why GLP GLP-1 Friendly labels on food

Abstract Purpose of Review This review explores the rationale and available evidence behind incretin-based therapies for metabolic dysfunction-associated steatotic disease (MASLD) and metabolic-associated steatohepatitis (MASH), focusing on glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptor dual agonists (GLP-1/GCG RAs)

They argue that the manufacturers knew about serious risks and either concealed them or minimized them in their labeling and marketing materials

Transparency and empathy are at the core of our approach

by Regina Schaffer Disclosure s : Martin is vice president of Lilly Medical Affairs

Named medical group: Not publicly disclosed in Omzo's consumer-facing materials as of June 2026

Price varies by dose level